Aditxt (NASDAQ: $ADTX) announced on Friday, February 21, 2025, that its Subsidiary, Pearsanta, had engaged the services of a lead underwriter as it prepares for an IPO targeting H2 2025. The goal of the IPO is to support Pearsanta’s commercial launch of an early cancer detection test in the US and globally.
Pearsanta’s Early Cancer Detection Test
The subsidiary is working on a non-invasive blood-based test that uses proprietary Mitomic® Technology. Its test utilizes deletions in mitochondrial DNA as biomarkers to detect disease. Pearsanta is currently working on clinical validation that includes a randomized controlled study of the Mitomic Prostate Test (MPT).
Thus far, it has submitted a $2.3M research proposal to evaluate the role of MPT in reducing unnecessary biopsies, with a decision due in H1 2025. It has also submitted another research proposal to validate the Mitomic Ovarian Test (MOT), which was not funded. The IPO will fund the launch of Laboratory Developed Tests, while driving global commercialization via regulatory approvals, and partnerships.
Commenting on the recent announcement, Aditxt CEO Amro Albanna said, “Cancer is one of the most pressing health challenges, and early detection is key to the fight against cancer.” He added, “We believe that this milestone is a critical step in Pearsanta’s path to commercialization, expanding its potential beyond oncology to a broader range of diseases where early intervention can have a meaningful impact.”
Key Highlights And Insights From The Announcement
Pearsanta’s engagement of Dominari Securities’ services for the IPO is a strategic move in the highly competitive cancer diagnostics market. According to a report by Fortune Business Insights, the global cancer diagnostics market is expected to grow to $31 billion by 2032.
Its unique funding strategy is also noteworthy. The company’s pending $2.3 million DoD proposal could provide useful validation for its technology. Additionally, its H2 2025 target signals confidence in its test, given the current stage of development.
Aditxt (NASDAQ: ADTX) Market Performance
Aditxt (ADTX) shares are up 23.57% in the past week to $0.0863 per share as of 12:02 PM EST on Monday, February 24, 2025. That could potentially signal investor enthusiasm regarding the planned IPO.
For ADTX shareholders, a successful IPO by Pearsanta could unlock value. However, factors to watch out for include the structure and Aditxt’s retained ownership stake.
Is Now The Time To Invest In Aditxt?
The broader cancer diagnostics market is forecast to grow to $31 billion by Fortune Business Insights. AS such adding ADTX to your portfolio potentially unlocks a massive investment opportunity. Given Aditxt’s relatively small market cap in a market dominated by mature players, it could potentially present an opportunity for growth.
Disclaimer: This website provides information about cryptocurrency and stock market investments. This website does not provide investment advice and should not be used as a replacement for investment advice from a qualified professional. This website is for educational and informational purposes only. The owner of this website is not a registered investment advisor and does not offer investment advice. You, the reader / viewer, bear responsibility for your own investment decisions and should seek the advice of a qualified securities professional before making any investment. We have been compensated twenty thousand dollars electronically via bank wire by One Eyed Jack Enterprises LLC for an advertising / marketing campaign for Aditxt, Inc. (NASDAQ: $ADTX) beginning on 2/24/2025 and ending on 3/05/2025. DEXWireNews may receive additional campaigns in the future by One Eyed Jack Enterprises LLC to distribute media for for Aditxt, Inc. (NASDAQ: $ADTX).